Subgroup analyses showed a @-year disease-specific survival benefit for patients with pathological tumour ( pT ) @ disease in the D@ group ( @ per cent versus @ per cent for the D@ group ; P = @ ) , and for patients with pT@-@ status and positive lymph nodes in the D@ group ( @ per cent versus @ per cent for the D@ group ; P = @ ) .